TITLE

Pass the Buck

AUTHOR(S)
Barr, Bill
PUB. DATE
January 2007
SOURCE
Pharmaceutical Representative;Jan2007, Vol. 37 Issue 1, p16
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on challenges of selling pharmaceuticals in a managed care environment in the United States. Two distinct entities exert enormous influence on a patient's decision to purchase and use a pharmaceutical product. The first influence is the physician. The organization or individual who pays for the prescription in the second influence.
ACCESSION #
23620470

 

Related Articles

  • Compounding challenges. Walker, Tracey // Managed Healthcare Executive;Jul2004, Vol. 14 Issue 7, p34 

    Reports on the challenge of compounded prescriptions on reimbursement, quality and cost issues to managed care organizations in the U.S. Increase in the number of compounded prescriptions with the growth of specialty and biotechnology drugs; Use of the traditional pharmacy reimbursement formula...

  • Pharmaceutical and Health Insurance Companies Seen In Negative Light By Public, Says New Survey.  // Insurance Advocate;7/12/2004, Vol. 115 Issue 25, p34 

    Reports decline in the ratings of pharmaceutical and health insurance industry. Difference between managed care and health insurance companies; Increase in hospital costs; Coverage to drug prices.

  • Formulary decision making might require some guidance. Walker, Tracey // Managed Healthcare Executive;Jan2006, Vol. 16 Issue 1, p13 

    The article provides information on principles that can guide formulary decisions that serve the purposes of improving patient safety and lowering costs. In the present situation of increasing pharmaceutical costs, managed care executives need to make an assessment of the benefits, risks and...

  • Managed care coverage for specific drug classes. Walker, Tracey // Managed Healthcare Executive;Mar2006, Vol. 16 Issue 3, p64 

    The article focuses on the challenges in pharmacy versus medical benefits for certain dug classes. There is uncertainty in coverage for sexual dysfunction, smoking prevention and anorexiant drugs. A chart about the classes of drugs and the percentage of plans offering them as a pharmacy benefit...

  • Just what the HMO ordered: The paradox of increasing drug costs. Kleinke, J.D. // Health Affairs;Mar/Apr2000, Vol. 19 Issue 2, p78 

    Focuses on problems concerning the increase of pharmaceutical products covered in managed care plans in the United States. Claims of health plans and pharmaceutical companies about drug costs; Role of health maintenance organizations in monitoring drug costs; Structure and distribution of...

  • Valuable drug education programs need a lifeline. Silva, Chris // Employee Benefit News Canada;Nov/Dec2006, Vol. 3 Issue 6, p12 

    The article reveals that health experts are encouraging Canada's health ministers to consider expanding continuing education for physicians. The expansion of continuing education for physicians will help to offset potentially biased drug information they received from pharmaceutical companies....

  • New pricing moves. Conlan, Michael F. // Drug Topics;5/23/94, Vol. 138 Issue 10, p60 

    Reports on developments in drug prices and the effect of managed care on the pharmaceutical industry. Maine's price discrimination legislation for the pharmaceutical industry; Medicaid patients' right to go to any pharmacy in Missouri; Proposed bill to curb prescription drug price abuses in...

  • A New Deal With Managed Care. Breitstein, Joanna // Pharmaceutical Executive;Sep2003, Vol. 23 Issue 9, p66 

    Focuses on the model for marketing pharmaceuticals to managed care in the U.S. Provision of information on the superiority of products by the pharmaceutical industry; Strategies for aligning the interests of patients, healthcare providers, and industry; Analysis of state management of...

  • Surveys find support in U.S. for drug importation surging. Johnsen, Michael // Drug Store News;9/27/2004, Vol. 26 Issue 12, p10 

    Presents survey result on the majority of Americans supporting drug importation in the U.S. Regulation of the managed care companies; Need for government-controlled pharmaceutical pricing; Legalization of pharmaceutical imports from Canada.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics